Effects of long-term mildronate treatment on cardiac and liver functions in rats

Basic and Clinical Pharmacology and Toxicology

Volumn 105, Issue 6, 2009, Pages 387-394

  Liepinsh, Edgars ^a   Kuka, Janis ^a,b   Svalbe, Baiba ^a   Vilskersts, Reinis ^a   Skapare, Elina ^a,b   Cirule, Helena ^a   Pugovics, Osvalds ^a   Kalvinsh, Ivars ^a   Dambrova, Maija ^a  

^a LATVIAN INSTITUTE OF ORGANIC SYNTHESIS   (Latvia)

^b RIGA STRADINS UNIVERSITY   (Latvia)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARNITINE; FATTY ACID; GAMMA BUTYROBETAINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MILDRONATE; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; FATTY ACID BLOOD LEVEL; HEART FUNCTION; HOMEOSTASIS; ISOLATED HEART; LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION; LIVER TOXICITY; MALE; MONITORING; NONHUMAN; PRIORITY JOURNAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; BETAINE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY WEIGHT; CARDIOVASCULAR AGENTS; CARNITINE; CARNITINE O-PALMITOYLTRANSFERASE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE; HEART; HEMODYNAMICS; LIPIDS; LIVER; LIVER GLYCOGEN; MALE; METHYLHYDRAZINES; MYOCARDIUM; RATS; RATS, WISTAR; TIME FACTORS; TOXICITY TESTS, CHRONIC;

RATTUS; RATTUS NORVEGICUS;

EID: 70449686023     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2009.00461.x     Document Type: Article

References (33)

1. Dambrova M, Liepinsh E, Kalvinsh I. Mildronate: cardioprotective action through carnitine-lowering effect. Trends Cardiovasc Med 2002 12 : 275 279.
2. Sjakste N, Gutcaits A, Kalvinsh I. Mildronate: an antiischemic drug for neurological indications. CNS Drug Rev 2005 11 : 151 168.
3. Hayashi Y, Kirimoto T, Asaka N, Nakano M, Tajima K, Miyake H et al. Beneficial effects of MET-88, a gamma-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction. Eur J Pharmacol 2000 395 : 217 224.
4. Yonekura K, Eto Y, Yokoyama I, Matsumoto A, Sugiura S, Momomura S et al. Inhibition of carnitine synthesis modulates protein contents of the cardiac sarcoplasmic reticulum Ca2+-ATPase and hexokinase type I in rat hearts with myocardial infarction. Basic Res Cardiol 2000 95 : 343 348.
5. Liepinsh E, Vilskersts R, Loca D, Kirjanova O, Pugovichs O, Kalvinsh I et al. Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction. J Cardiovasc Pharmacol 2006 48 : 314 319.
6. Sesti C, Simkhovich BZ, Kalvinsh I, Kloner RA. Mildronate, a novel fatty acid oxidation inhibitor and antianginal agent, reduces myocardial infarct size without affecting hemodynamics. J Cardiovasc Pharmacol 2006 47 : 493 499.
7. Chumburidze V, Kikalishvili T, Sulashvili T. Definition of therapeutic effect of mildronate in patients with chronic heart failure. Georgian Med News 2005 122 : 25 9.
8. Statsenko ME, Belenkova SV, Sporova OE, Shilina NN. The use of mildronate in combined therapy of postinfarction chronic heart failure in patients with type 2 diabetes mellitus. Klin Med (Mosk) 2007 85 : 39 42.
9. Simkhovich BZ, Shutenko ZV, Meirena DV, Khagi KB, Mezapuke RJ, Molodchina TN et al. 3-(2,2,2-Trimethylhydrazinium)propionate (THP)-a novel gamma-butyrobetaine hydroxylase inhibitor with cardioprotective properties. Biochem Pharmacol 1988 37 : 195 202.
10. Kuwajima M, Harashima H, Hayashi M, Ise S, Sei M, Lu K et al. Pharmacokinetic analysis of the cardioprotective effect of 3-(2,2,2- trimethylhydrazinium) propionate in mice: inhibition of carnitine transport in kidney. Pharmacol Exp Ther 1999 289 : 93 102.
11. Liepinsh E, Vilskersts R, Skapare E, Svalbe B, Kuka J, Cirule H et al. Mildronate decreases carnitine availability and up-regulates glucose uptake and related gene expression in the mouse heart. Life Sci 2008 83 : 613 619.
12. Burkhoff D, Weiss RG, Schulman SP, Kalil-Filho R, Wannenburg T, Gerstenblith G. Influence of metabolic substrate on rat heart function and metabolism at different coronary flows. Am J Physiol 1991 261 : 741 750.
13. Opie LH. Myocardial ischemia-metabolic pathways and implications of increased glycolysis. Cardiovasc Drugs Ther 1990 4 : 777 790.
14. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005 85 : 1093 1129.
15. Bremer J. Carnitine-metabolism and functions. Physiol Rev 1983 63 : 1420 1480.
16. Vaz FM, Wanders RJ. Carnitine biosynthesis in mammals. Biochem J 2002 361 : 417 429.
17. Degrace P, Demizieux L, Gresti J, Tsoko M, Andre A, Demaison L et al. Fatty acid oxidation and related gene expression in heart depleted of carnitine by mildronate treatment in the rat. Mol Cell Biochem 2004 258 : 171 182.
18. Degrace P, Demizieux L, Du ZY, Gresti J, Caverot L, Djaouti L et al. Regulation of lipid flux between liver and adipose tissue during transient hepatic steatosis in carnitine-depleted rats. J Biol Chem 2007 282 : 20816 20826.
19. Spaniol M, Kaufmann P, Beier K, Wuthrich J, Torok M, Scharnagl H et al. Mechanisms of liver steatosis in rats with systemic carnitine deficiency due to treatment with trimethylhydraziniumpropionate. J Lipid Res 2003 44 : 144 153.
20. Zaugg CE, Spaniol M, Kaufmann P, Bellahcene M, Barbosa V, Tolnay M et al. Myocardial function and energy metabolism in carnitine-deficient rats. Cell Mol Life Sci 2003 60 : 767 775.
21. Dambrova M, Cirule H, Svalbe B, Zvejniece L, Pugovichs O, Zorenko T et al. Effect of inhibiting carnitine biosynthesis on male rat sexual performance. Physiol Behav 2008 95 : 341 347.
22. Karlic H, Lohninger S, Koeck T, Lohninger A. Dietary l-carnitine stimulates carnitine acyltransferases in the liver of aged rats. J Histochem Cytochem 2002 50 : 205 212.
23. Bieber LL. Carnitine. Annu Rev Biochem 1988 57 : 261 283.
24. Foster DW. The role of the carnitine system in human metabolism. Ann N Y Acad Sci 2004 1033 : 1 16.
25. Mingrone G. Carnitine in type 2 diabetes. Ann N Y Acad Sci 2004 1033 : 99 107.
26. Stephens FB, Constantin-Teodosiu D, Greenhaff PL. New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle. J Physiol 2007 581 : 431 444.
27. Ramsay RR, Gandour RD, van der Leij FR. Molecular enzymology of carnitine transfer and transport. Biochim Biophys Acta 2001 1546 : 21 43.
28. Rebouche CJ, Mack DL. Sodium gradient-stimulated transport of L-carnitine into renal brush border membrane vesicles: kinetics, specificity, and regulation by dietary carnitine. Arch Biochem Biophys 1984 235 : 393 402.
29. Hmelnickis J, Pugovics O, Kazoka H, Viksna A, Susinskis I, Kokums K. Application of hydrophilic interaction chromatography for simultaneous separation of six impurities of mildronate substance. J Pharm Biomed Anal 2008 48 : 649 656.
30. Uenaka R, Kuwajima M, Ono A, Matsuzawa Y, Hayakawa J, Inohara N et al. Increased expression of carnitine palmitoyltransferase I gene is repressed by administering L-carnitine in the hearts of carnitine-deficient juvenile visceral steatosis mice. J Biochem 1996 119 : 533 540.
31. Ijlst L, Mandel H, Oostheim W, Ruiter JP, Gutman A, Wanders RJ. Molecular basis of hepatic carnitine palmitoyltransferase I deficiency. J Clin Invest 1998 102 : 527 531.
32. Long CS, Haller RG, Foster DW, McGarry JD. Kinetics of carnitine-dependent fatty acid oxidation: implications for human carnitine deficiency. Neurology 1982 32 : 663 666.
33. McGarry JD, Mills SE, Long CS, Foster DW. Observations on the affinity for carnitine, and malonyl-CoA sensitivity, of carnitine palmitoyltransferase I in animal and human tissues. Demonstration of the presence of malonyl-CoA in non-hepatic tissues of the rat. Biochem J 1983 214 : 21 8.